Articles related to PEDIATRIC NEUROLOGY
FDA Grants Orphan Drug Designation to Exon 44 Skipping AOC for Duchenne Muscular Dystrophy
Discover how AOC 1044’s recent FDA orphan drug designation could revolutionize the treatment landscape for Duchenne muscular dystrophy patients with exon 44 mutations. Stay tuned for upcoming results from the EXPLORE44 trial.
Neurology August 30th 2023